Chromoblastomycosis
Solutions
Online Inquiry

Chromoblastomycosis

Chromoblastomycosis stands as a persistent and neglected subcutaneous mycosis, induced by various fungi species belonging to the Herpotrichiellaceae family. Our company spearheads innovation in the domain of infectious diseases such as chromoblastomycosis, delivering a holistic spectrum of services tailored to cater to the requisites of researchers and scientists delving into this specialized field.

Overview of Chromoblastomycosis

This chronic fungal infection, chromoblastomycosis, infiltrates the skin and subcutaneous tissues, orchestrated by fungi strains like Fonsecaea pedrosoi, Cladophialophora carrionii, and Phialophora verrucosa hailing from the Herpotrichiellaceae lineage. Exhibiting a striking propensity for tropical and subtropical climates, with prevalence figures of 1:6800 in Madagascar and 1:196,000 in Brazil, chromoblastomycosis manifests in various forms including nodular, tumoral type, verrucous, plaque, and cicatricial.

Overview of chromoblastomycosis.Fig.1 Acquired immune responses and outcome of chromoblastomycosis. (Passero, L. F. D., et al., 2021)

Pathogenesis of Chromoblastomycosis

The etiology of chromoblastomycosis entails the incisive introduction of fungal spores into the skin, resulting in the formation of chronic granulomatous lesions. The chronic nature of the infection is attributed to the ability of these fungi to evade the immune system and form biofilms, making therapy challenging. A few days after infection, the fungal entity transforms muriform cells ensconced within phagocytic cells. These muriform or sclerotic cells are characterized by their rounded morphology, multicellular septation, and pigmentation.

Pathogenesis of chromoblastomycosis.Fig.2 A prototype scheme of induction of innate immunity in chromoblastomycosis. (Passero, L. F. D., et al., 2021)

Vaccine and Therapeutic Development for Chromoblastomycosis

Types Names Mechanism of Action Targets Research Phase
DNA Vaccine DNA-hsp65 vaccine Reduction in NO production Hsp65 Preclinical research
Small molecule drug Amphotericin B Formed channels that cause leakage of fungal cell components and death Ergosterol Approved
Itraconazole Inhibit the demethylation of lanosterol and consequently the production of fungal ergosterol CYP51A1 Approved
Acitretin Inhibit endothelial growth and angiogenesis RARs Approved
Imiquimod Stimulate the immune response TLR 7/8 Approved
Ajoene Inhibit the biosynthesis of phosphatidylcholine, a cell membrane component / Clinical research
Monoclonal antibody Mab anti-GlcCer Fungistatic and fungicidal activities GlcCer Preclinical research
Purified antibodies anti-Melanin Fungicidal activities Melanin Preclinical research
Photodynamic therapy Methylene blue-LED Product reactive oxygen species and other reactive molecules / Clinical research

Our Services

Leveraging an advanced platform tailored for disease modeling, vaccine development, and therapeutic exploration, our company provides a conduit to an assortment of tools, technologies, and specialized knowledge requisite for elucidating pathogenesis, devising therapy modalities, and exploring potential interventions for infections like chromoblastomycosis.

Featured Services for Chromoblastomycosis

Why Choose Us

With a dedicated focus on infectious diseases, we provide a unique advantage by combining cutting-edge research support, access to state-of-the-art laboratory facilities, expert consultation services, and a wide array of resources essential for studying and combating these complex diseases effectively.

If you are interested in our service, we encourage you to contact us for more information tailored to your specific research needs.

References

  1. Passero, Luiz Felipe Domingues et al. "Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis." Journal of immunology research (2021): 9742832.
  2. Breda, Leandro C D et al. "Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis." Journal of fungi (Basel, Switzerland) 7.1 (2020): 3.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.